In Vivo CAR-T Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$652M

Range: $344M - $949M

Total Deal Value

$3.5B

Range: $2.1B - $4.8B

Royalty Rate

14.6% - 24.3%

Tiered up to 28.3%

Dev Milestones

$560M

Range: $359M - $763M

Model Your Deal

Market Analysis

In Vivo CAR-T therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 in vivo car-t asset in immunology & autoimmune is $652M, with total deal values reaching $3.5B. Development milestones average $560M, while regulatory milestones contribute $980M.

The immunology & autoimmune in vivo car-t landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for in vivo car-t immunology & autoimmune deals range from 14.6% to 24.3% at the base tier, with tiered escalation reaching 18.6%-28.3% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a in vivo car-t immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 in vivo car-t licensing deals in immunology & autoimmune average $652M in upfront payments, with a range of $344M to $949M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for in vivo car-t immunology & autoimmune transactions?

The median total deal value for Phase 2 in vivo car-t assets in immunology & autoimmune is $3.5B, ranging from $2.1B to $4.8B. This includes development milestones ($560M), regulatory milestones ($980M), and commercial milestones ($1.3B).

What royalty rates are standard for in vivo car-t deals in immunology & autoimmune?

Base royalty rates for in vivo car-t immunology & autoimmune transactions range from 14.6% to 24.3%, with tiered escalations reaching 18.6%-28.3% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in in vivo car-t immunology & autoimmune deals?

In Vivo CAR-T immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($560M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($980M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included